Ahmed M. Hamdy

Person

Last mentioned: Mar 20, 2026

Timeline

  1. ASH Annual Meeting

    Targeted presentation of initial proof-of-concept data for TakeAim CLL study.

  2. Q4 Earnings Report

    Reported $19.4M net income and updated clinical guidance for emavusertib.

  3. PIPE Financing

    Secured $20.2 million in initial proceeds with milestone-linked upside.

  4. Erivedge Wind-down

    Final Erivedge royalties received before the transition to Oberland.

Stories mentioning Ahmed M. Hamdy 1

clinical-trial Neutral

Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale

Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.

4 sources